Roche reports Q3 earnings - looks to Tecentriq for future
Roche's pharma revenues declined in the third quarter, but the Swiss major pharma company is looking towards their immune checkpoint inhibitor Tecentriq in adjuvant settings to boost future revenues.
Consequently, ONCY's pancreatic results from the Goblet Phase 2 clinical study could be what leads Roche's gains involving Teccentriq in combination with ONCY's pelareorep.
We will gain more insight into the positive results of the Goblet panceatic cancer cohort on November 11th at the SITC 2022 - 37th Annual Meeting.
https://www.oncolyticsbiotech.com/press-releases/detail/582/oncolytics-biotech-announces-upcoming-presentations-at